Data Year:
Select Other Years

For its 2023 fiscal year, DECIPHERA PHRMCTAL INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2023
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Daniel L. Flynn Ph.D.
Founder and Former EVP, Chief Scientific Officer
Total Compensation $1,999,385 View details Pay Rank By Title In Biotechnology industry #114 View more
Thomas P. Kelly
EVP, Chief Financial Officer & Treasurer
Total Compensation $2,030,801 View details Pay Rank By Title In Biotechnology industry #235 View more
Daniel C. Martin
Chief Commercial Officer
Total Compensation $1,578,908 View details Pay Rank By Title In Biotechnology industry #213 View more
Steven L. Hoerter
President and Chief Executive Officer
Total Compensation $6,010,712 View details Pay Rank By Title In Biotechnology industry #225 View more
Matthew L. Sherman M.D.
EVP, Chief Medical Officer
Total Compensation $2,128,911 View details Pay Rank By Title In Biotechnology industry #109 View more
Dahyant Dhanak Ph.D.
EVP, Chief Scientific Officer
Total Compensation $3,063,207 View details Pay Rank By Title In Biotechnology industry #77 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at DECIPHERA PHRMCTAL INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. DECIPHERA PHRMCTAL INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. DECIPHERA PHRMCTAL INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Daniel L. Flynn Ph.D.
Founder and Former EVP, Chief Scientific Officer
Total Cash $501,970 Equity $1,258,328 Other $239,087 $1,999,385
Thomas P. Kelly
EVP, Chief Financial Officer & Treasurer
Total Cash $759,273 Equity $1,258,328 Other $13,200 $2,030,801
Daniel C. Martin
Chief Commercial Officer
Total Cash $714,334 Equity $851,374 Other $13,200 $1,578,908
Steven L. Hoerter
President and Chief Executive Officer
Total Cash $1,225,412 Equity $4,772,100 Other $13,200 $6,010,712
Matthew L. Sherman M.D.
EVP, Chief Medical Officer
Total Cash $857,383 Equity $1,258,328 Other $13,200 $2,128,911
Dahyant Dhanak Ph.D.
EVP, Chief Scientific Officer
Total Cash $492,455 Equity $2,564,752 Other $6,000 $3,063,207
For its 2023 fiscal year, DECIPHERA PHRMCTAL INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Steven L. Hoerter CEO Pay $6,010,712 Median Employee Pay $286,140 CEO Pay Ratio 21:1
For its 2023 fiscal year, DECIPHERA PHRMCTAL INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Dennis L. Walsh Total Cash $386,053
Edward J. Benz, Jr., M.D. Total Cash $396,093
Frank S. Friedman Total Cash $382,303
James A. Bristol, Ph.D. Total Cash $414,767
John R. Martin Total Cash $388,593
Patricia L. Allen Total Cash $398,553
Ron Squarer Total Cash $403,295
Susan L. Kelley, M.D. Total Cash $396,053
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.